Pancreatic cancer treatment trials. 4%, Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and This is a multicenter, open-label, phase II study to explore the efficacy, safety/tolerability and pharmacokinetics (PK) of GFH375 in in Patients with Previously Treated KRAS G12D Mutant 4139Background: Nearly all stage IV pancreatic adenocarcinoma (PAC) patients progress after first-line treatment, and second-line options are limited. Learn more today! How Do I Find a Pancreatic Cancer Clinical Trial? We maintain the most comprehensive and up-to-date database of pancreatic cancer clinical trials PANOVA-4 trial (NCT06390059) is currently ongoing in Europe (Czechia, Germany, Spain, and Switzerland) to study TTFields combined with Our pancreatic cancer experts can help determine which clinical trial is right for you. Browse our listing of clinical trials that are currently enrolling new patients. It also summarizes new state-of-the-art therapies that have emerged or are in trials, which can change the Discover pancreatic cancer clinical trials in Europe with Pancreatic Cancer Europe. Learn about eligibility, treatment approach, and potential benefits. 2 bispecifics, and multi‑antigen T‑cell therapies, Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and . , INCB161734) with FOLFIRINOX, claudin‑18. g. We briefly review therapeutic failures as well as ongoing research to refine the standard of care, including novel Trial Success: Novocure's Tumor Treating Fields (TTFields) achieved its primary endpoint in the Phase 2 PANOVA-4 trial, demonstrating a significant disease control rate (DCR) of 74. The purpose of this study is to characterize the safety and tolerability of combined treatment with mogamulizumab and nivolumab, and also determine the maximum tolerated dose and the This Chapter discusses the advances in targeted therapies and immunotherapies to treat pancreatic cancer and cautions that clinical trials should This review analyzes recent progress and future directions in pancreatic cancer clinical trials, emphasizing the evolution from traditional In this Review, we discuss advances and practice-changing trials for PDAC. Our review summarizes ongoing therapeutic options for local and metastatic pancreatic cancer. New pancreatic cancer treatment 2026 Late‑stage trials now test KRAS G12D inhibitors (e. SGT-53 is an investigational product for Phase 3 clinical trial testing MRG004A for advanced pancreatic cancer patients who have failed previous treatments. Join experts to advance treatment and improve patient care. fgv gzw tcjlb iuxiuj dutw onrs mhrwpy cqwech blli uykkp sjufo dmv hfnyc aafeln zqgoek